Last reviewed · How we verify
glioblastoma multiforme multipeptide vaccine IMA950 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
glioblastoma multiforme multipeptide vaccine IMA950 (glioblastoma multiforme multipeptide vaccine IMA950) — Cancer Research UK.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| glioblastoma multiforme multipeptide vaccine IMA950 TARGET | glioblastoma multiforme multipeptide vaccine IMA950 | Cancer Research UK | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- glioblastoma multiforme multipeptide vaccine IMA950 CI watch — RSS
- glioblastoma multiforme multipeptide vaccine IMA950 CI watch — Atom
- glioblastoma multiforme multipeptide vaccine IMA950 CI watch — JSON
- glioblastoma multiforme multipeptide vaccine IMA950 alone — RSS
Cite this brief
Drug Landscape (2026). glioblastoma multiforme multipeptide vaccine IMA950 — Competitive Intelligence Brief. https://druglandscape.com/ci/glioblastoma-multiforme-multipeptide-vaccine-ima950. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab